Valuation: Tonix Pharmaceuticals Holding Corp

Market Cap 191M 165M 154M 142M 266M 18.2B 271M 1.81B 710M 9.12B 718M 702M 30.16B P/E 2026 *
-1.19x
P/E 2027 * -1.9x
Enterprise Value 191M 165M 154M 142M 266M 18.2B 271M 1.81B 710M 9.12B 718M 702M 30.16B EV / Sales 2026 *
5.59x
EV / Sales 2027 * 2.42x
Free-Float
99.86%
Yield 2026 *
-
Yield 2027 * -
04/08 Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US CI
22/07 Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026 CI
16/07 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
13/07 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
13/07 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
29/06 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
29/06 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
25/06 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
08/06 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
08/06 Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA CI
29/05 Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting CI
27/05 Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody CI
26/05 Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment CI

Last Transcript: Tonix Pharmaceuticals Holding Corp

Manager TitleAgeSince
Chief Executive Officer 68 16/11/2007
Director of Finance/CFO 52 01/02/2016
Chief Tech/Sci/R&D Officer 57 04/02/2025
Director TitleAgeSince
Chairman 68 01/10/2011
Director/Board Member 66 12/09/2017
Director/Board Member 81 05/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.52%+2.66%+58.86%+163.79% 1,062B
+0.88%+1.34%+51.97%+53.36% 619B
+0.89%-4.42%+25.34%+66.55% 431B
+0.71%+3.93%+47.75%+38.58% 358B
+0.64%-0.63%+36.39%+41.44% 293B
+0.39%-6.48%+7.62%+9.04% 247B
+1.51%+6.01%+44.36%+68.92% 219B
+3.92%-7.80%+5.39%-42.52% 200B
+1.80%+1.47%+20.79%+69.31% 162B
Average +1.08%-1.90%+33.16%+52.05% 399.14B
Weighted average by Cap. +0.62%-0.83%+41.60%+78.43%

Financials

2026 *2027 *
Net sales 34.18M 29.58M 27.61M 25.34M 47.64M 3.25B 48.37M 324M 127M 1.63B 128M 126M 5.39B 78.93M 68.3M 63.75M 58.52M 110M 7.51B 112M 748M 293M 3.76B 296M 290M 12.45B
Net income -168M -145M -136M -125M -234M -16.01B -238M -1.59B -624M -8.02B -631M -618M -26.52B -152M -132M -123M -113M -212M -14.51B -216M -1.44B -566M -7.27B -572M -560M -24.04B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-